6533b833fe1ef96bd129ba1b
RESEARCH PRODUCT
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases
Michelle SterpiMaria Antonietta SatolliSalvatore IntagliataToni IbrahimL. GinocchiBruno VincenziVincenzo AdamoRaffaele AddeoAlfredo FalconeFilippo De MarinisGiuseppe BadalamentiCinzia OrtegaAntonio RussoNicla La VerdeFlavia LongoDaniele SantiniGaetano LanzettaDavide OttavianiGiovanni MansuetoEnrico VasileFlavia CantileFrancesco FerraùFausto PetrelliGiuseppe ToniniElena CollovàFrancesca Maria TancaSandro BarniLuca MoscettiFrancesco PantanoAndrea MancusoDomenico GalettaMarco Russanosubject
OncologyAdultMalemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentECOG Performance StatusBone NeoplasmsYoung AdultInternal medicineCarcinomamedicine80 and overHumansYoung adultLung cancerNon-Small-Cell LungAgedLungMultidisciplinarybusiness.industryAdult Aged Aged 80 and over Bone Neoplasms Carcinoma Non-Small-Cell Lung Female Humans Lung Neoplasms Male Middle Aged Young Adult Disease Progression MultidisciplinaryCarcinomaBone metastasisMiddle Agedmedicine.diseaseRadiation therapymedicine.anatomical_structureConcomitantDisease ProgressionFemaleAdult; Aged; Aged 80 and over; Bone Neoplasms; Carcinoma Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Young Adult; Disease Progressionbusinessdescription
AbstractWe conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median survival after bone metastases diagnosis was 9.5 months and after the first skeletal-related event was 7 months. We created a score based on four factors used to predict the overall survival from the diagnosis of bone metastases: age >65 years, non-adenocarcinoma histology, ECOG Performance Status >2, concomitant presence of visceral metastases at the bone metastases diagnosis. The presence of more than two of these factors is associated with a worse prognosis.This study demonstrates that patients affected by Non-Small Cell Lung Cancer with bone metastases represent a heterogeneous population in terms of risk of skeletal events and survival.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-12-22 |